Padmaja, S. and Mohan, J. (2021) A Short on Ubrogepant. Journal of Pharmaceutical Research International, 33 (56A). pp. 79-81. ISSN 2456-9119
4651-Article Text-6738-1-10-20221006.pdf - Published Version
Download (299kB)
Abstract
Migraine is a mysterious disorder characterized by pulsating head ache, which is actually characterized to one side and comes in attacks which will be lasting for about 3-48 hours and can be associated with nausea,vomiting,sensitivity to sound,flashes of light,vertigoand diarrhoea [1]. Most of the drugs which are in current use for actue migraine like triptans, treats the disorder symptomatically. A novel group of drugs has been in research for the migraine which treats the disorder pathologically. Calcitonin gene – related peptide (CGRP) has a major role in the pathophysiology of the disorder and hence CGRP receptor antagonist, known as Gepants are in the research process [2]. Gepants are being studied for the efficacy of treating acute migraine [2]. This article will be a review article about the drug – Ubrogepant, which is approved for treatment of migraine with acute attacks in adults [3].
Item Type: | Article |
---|---|
Subjects: | GO for STM > Medical Science |
Depositing User: | Unnamed user with email support@goforstm.com |
Date Deposited: | 08 Mar 2023 11:17 |
Last Modified: | 22 Dec 2023 07:10 |
URI: | http://archive.article4submit.com/id/eprint/122 |